Chemed (NYSE:CHE) Releases FY 2026 Earnings Guidance

Key Points

• Chemed issued FY 2026 EPS guidance of $25.00–$25.75, above the consensus estimate of $24.01; no revenue guidance was provided.
• Chemed shares rose 1.3% to $516.09, near their 52-week high, while analysts maintained a consensus “Hold” rating with a $480.25 target price.
• The company declared a quarterly dividend of $0.60 per share, or $2.40 annualized, representing a 0.5% yield and a 13.08% payout ratio.

Chemed (NYSE:CHE - Get Free Report) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 25.000-25.750 for the period, compared to the consensus EPS estimate of 24.010. The company issued revenue guidance of -.

Chemed Stock Up 1.3%

Shares of NYSE CHE traded up $6.75 during midday trading on Tuesday, hitting $516.09. 198,344 shares of the stock traded hands, compared to its average volume of 222,959. The company has a market cap of $6.85 billion, a PE ratio of 28.12, a P/E/G ratio of 1.88 and a beta of 0.52. Chemed has a one year low of $365.20 and a one year high of $520.01. The business has a 50 day moving average price of $459.92 and a two-hundred day moving average price of $434.09. The company has a debt-to-equity ratio of 0.11, a quick ratio of 0.83 and a current ratio of 0.85.

Chemed Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Thursday, May 28th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Thursday, May 28th. Chemed's payout ratio is 13.08%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CHE. Bank of America raised their price objective on shares of Chemed from $450.00 to $510.00 and gave the company a "neutral" rating in a research note on Thursday, July 9th. Zacks Research upgraded shares of Chemed from a "strong sell" rating to a "hold" rating in a report on Monday, April 27th. Wall Street Zen cut shares of Chemed from a "buy" rating to a "hold" rating in a research report on Monday, June 8th. Weiss Ratings raised Chemed from a "hold (c-)" rating to a "hold (c)" rating in a report on Friday, July 17th. Finally, Royal Bank Of Canada increased their price target on Chemed from $422.00 to $436.00 and gave the company a "sector perform" rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $480.25.

Insider Activity

In other Chemed news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $421.13, for a total transaction of $842,260.00. Following the transaction, the chief executive officer owned 90,219 shares of the company's stock, valued at $37,993,927.47. This trade represents a 2.17% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrea R. Lindell sold 1,347 shares of the company's stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $447.33, for a total value of $602,553.51. Following the completion of the transaction, the director directly owned 4,578 shares of the company's stock, valued at approximately $2,047,876.74. This represents a 22.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 3.33% of the company's stock.

Institutional Investors Weigh In On Chemed

Several large investors have recently made changes to their positions in the business. Los Angeles Capital Management LLC bought a new position in Chemed during the fourth quarter valued at about $26,000. Global Retirement Partners LLC raised its position in Chemed by 200.0% in the fourth quarter. Global Retirement Partners LLC now owns 87 shares of the company's stock worth $37,000 after acquiring an additional 58 shares during the period. Geneos Wealth Management Inc. boosted its stake in Chemed by 330.4% in the first quarter. Geneos Wealth Management Inc. now owns 99 shares of the company's stock valued at $61,000 after acquiring an additional 76 shares during the last quarter. Employees Retirement System of Texas bought a new position in shares of Chemed during the 3rd quarter valued at approximately $64,000. Finally, Caitong International Asset Management Co. Ltd increased its stake in shares of Chemed by 5,333.3% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 163 shares of the company's stock worth $73,000 after purchasing an additional 160 shares during the last quarter. 95.85% of the stock is owned by hedge funds and other institutional investors.

About Chemed

Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.

The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source